Is Ascendis Pharma A/S (ASND) a Buy, Sell, or Hold?
NASDAQ : ASND
Ascendis Pharma A/S
$243.45 USD
-$0.46 (-0.19%)
- Volume
- 519.5K
- Average Volume
- 686.46K
- Market Capitalization
- $15.12B
- P/E Ratio
- 25.82
- Dividend Yield
- 0.00%
- Price Target
- $277.50
- Year High
- $282.15
- Year Low
- $173.33
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.00
Company Overview
NASDAQ
Jan Moller Mikkelsen
Biotechnology
Healthcare
ASND
1017
DK
USD
Liquidity Metrics
1.84
1.00
0.72
0.51
0.00
Sales & Valuation
$691.71M
15.14
26.70
311.92
0.68
Profitability
-$3.62
-$219.03M
58.40%
-19.34%
-5641.90%
25.26%
P/E Metrics
25.82
0.05
0.05
Analyst Price Target & Rating
$277.50
$345.00
$255.00
3/5
25 Analysts
-12.27%
Financial Health Scores
4.16
5/9
-$4.43M
$2.01B
$1.52B
-$5.03M
Key Metrics (TTM)
$13.46B
15.52
1088.39
1.00
-5641.90%
1.51%
3.88%
0.32%
$38.26
922 days
Company Executives
| Name | Title |
|---|---|
| Stina Singel | Executive Vice President & Head of Clinical Development for Oncology |
| Michael Wolff Jensen | Executive Vice President, Chief Legal Officer & Member of the Executive Board |
| Pedersen Anni Lotte Kirstine Sonderbjerg | Executive Vice President, Chief Administrative Officer & Member of the Executive Board |
| Jan Moller Mikkelsen | President, Chief Executive Officer, Member of Executive Board & Executive Director |
| Kennett Sprogoe | Executive Vice President and Head of Research & Product Development |
| Mads Bodenhoff | Senior Vice President, Head of Finance & Principal Accounting Officer |
| Joseph Kelly | Head of U.S. Commercial of Endocrinology |
| Chad Fugure | Vice President of Investor Relations |
| Flemming Steen Jensen | Executive Vice President of Product Supply & Quality |
| Scott T. Smith | Chief Financial Officer, Executive Vice President & Member of Executive Board |
Poll Results
No votes yet today — be the first to share your view!
About Ascendis Pharma A/S (NASDAQ:ASND) Stock
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonis ... t for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Why Crinetics Stock Soared 99% This Week
2026-07-09 13:29:39
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
14 value stocks of companies primed for rapid growth through 2028
2026-07-01 12:10:00
Let us begin with a midyear summary of index results that might surprise you in light of the triple-digit gains for so many growth stocks in the S&P 500.
2026-06-30 08:30:00
COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements in tibial-femoral angle (TFA). As previously reported, improvements in annualized growth velocity were maintained and ACH-specific height Z-score increased with TransCon CNP treatment through Week 104. The data were presented by Leanne M. Ward, M.D., FRCPC, Professor of Pediatrics at the University of Ottawa and Children's Hospital of Eastern Ontario, during the 12th International Conference on Children's Bone Health (ICCBH 2026) held in Montreal, Canada.
2026-06-26 16:01:00
COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026.
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
2026-06-26 11:45:28
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
2026-06-25 16:01:00
COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with achondroplasia will be shared in an oral presentation and two posters at ICCBH 2026, the 12th International Conference on Children's Bone Health being held in Montreal from June 27-30. The data include an oral presentation of Week 104 data showing improvements in lower-extremity alignment from the recently completed pivotal ApproaCH Trial of TransCon® CNP (navepegritide) by Leanne Ward, M.D., Professor of Pediatrics in the Faculty of Medicine at the University of Ottawa (Canada), as well as a late-breaking poster of radiographic and anthropometric data from Week 52 of the COACH Trial of combination therapy with TransCon CNP and TransCon hGH (lonapegsomatropin).
2026-06-13 16:00:00
COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.
Touchstone Mid Cap Growth Fund Q1 2026 Portfolio Review
2026-06-12 09:55:00
The Touchstone Mid Cap Growth Fund (Class A Shares, Load Waived) outperformed its benchmark, the Russell Midcap Growth Index, for the quarter ended March 31, 2026. Among the top contributors to relative performance during the quarter were Vertiv Holdings, Ascendis Pharma, Howmet Aerospace, Diamondback Energy, and Roblox Corp. The largest detractors from relative performance during the quarter were Atlassian Corp., DoorDash Inc., Ares Management, Axon Enterprise, and MongoDB.
Frequently Asked Questions
-
What is the current Ascendis Pharma A/S (ASND) stock price?
-
Ascendis Pharma A/S(NASDAQ:ASND) stock price is $243.45 in the last trading session. During the trading session, ASND stock reached the peak price of $282.15 while $173.33 was the lowest point it dropped to. The percentage change in ASND stock occurred in the recent session was --0.19% while the dollar amount for the price change in ASND stock was -$0.46.
-
ASND's industry and sector of operation?
-
The NASDAQ listed ASND is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ASND?
-
Stina Singel | Executive Vice President & Head of Clinical Development for Oncology
Michael Wolff Jensen | Executive Vice President, Chief Legal Officer & Member of the Executive Board
Pedersen Anni Lotte Kirstine Sonderbjerg | Executive Vice President, Chief Administrative Officer & Member of the Executive Board
Jan Moller Mikkelsen | President, Chief Executive Officer, Member of Executive Board & Executive Director
Kennett Sprogoe | Executive Vice President and Head of Research & Product Development -
How many employees does ASND have?
-
Number of ASND employees currently stands at 1017. ASND operates from Tuborg Boulevard 12, Hellerup, CR 2900, DK.
-
Link for ASND official website?
-
Official Website of ASND is: https://ascendispharma.com
-
How do I contact ASND?
-
ASND could be contacted at phone #45 70 22 22 44 and can also be accessed through its website. ASND operates from Tuborg Boulevard 12, Hellerup, CR 2900, DK.
-
How many shares of ASND are traded daily?
-
The average number of ASND shares traded daily for last 3 months was 686.46K.
-
What is the market cap of ASND currently?
-
The market value of ASND currently stands at $15.12B with its latest stock price at $243.45